Cxbladder Monitor was developed and validated by a multicenter clinical study on a prospective cohort of 763 patients with 1,036 individual samples, from patients with a history of UC who were undergoing standard investigation, including cystoscopy to rule out recurrent UC. 

The study found that the Cxbladder Monitor test significantly outperforms current FDA-approved urine-based tests, as well as cytology, in surveillance for recurrent UC.




  • References

    Kavalieris L, O’Sullivan PJ, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426. [pdf available]

    Lotan Y, Hershey JR, Shariat S, et al. The development and clinical validation of a high sensitivity urine biomarker test for the determination of recurrence in urothelial carcinoma patients. American Urological Association Annual Meeting 2016; San Diego, CA, USA. Read abstract

    Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017;:1–8. [pdf available]